615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Commercially Available Therapy, excluding Transplantation II
Jorge Sierra, Pau Montesinos, Xavier Thomas, et al.
Authors Conclusion from the Abstract: Midostaurin plus CT resulted in high response rates regardless of pt age, sex, induction drug, or alternative CT regimen. The majority of pts received a 7+3 regimen regardless of age. The safety profile of midostaurin plus idarubicin or daunorubicin for induction was generally similar. The safety profile in older and younger pts was consistent with what has been previously reported, with no new safety signals identified.
Timothy S. Pardee, Kristin M. Pladna, Susan Lyerly, et al.
Authors Conclusion from the Abstract: Selinexor in combination with standard induction and consolidation therapy appears highly active in older patients with de novo AML. Selinexor may increase response to cytarabine by interfering with nuclear-mitochondrial communication. Enrollment is ongoing.
Jorge Labrador, David Martínez-Cuadrón, Adolfo de la Fuente, et al.
Authors Conclusion from the Abstract: This is a large retrospective comparison with long-term follow-up of clinical outcomes associated with AZA and DEC treatment for patients with AML patients not eligible for intensive chemotherapy. There were no significant differences in ORR, CR/CRi or OS between AZA and DEC. However, patients with WBC ≥ 10 x109/L, platelet count <20 x109/L and estimated glomerular filtrate rate ≥ 45 mL/min/1.73m2 could benefit from AZA in terms of OS.
Jeffrey E. Lancet, Geoffrey L Uy, Laura F. Newell, et al.
Authors Conclusion from the Abstract: After 5 y of follow-up, improved OS with CPX-351 versus conventional 7+3 chemotherapy was maintained in this phase 3 study in the overall study population regardless of patient age, in those who underwent HCT, and among patients who achieved CR or CRi. The longer OS with CPX-351 versus 7+3 in patients who underwent HCT and in those who achieved CR or CRi suggests potentially deeper responses may be achieved with CPX-351. These data support prior evidence that CPX-351 has the ability to produce or contribute to long-term remission and survival in older patients with newly diagnosed high-risk/secondary AML.
Eytan M. Stein, Ying Huang, Uma Borate, et al.
Authors Conclusion from the Abstract: In newly diagnosed pts ≥60 years old with IDH2m AML, ENA had a low early death rate, high CR/CRi rate (47%, adjusted 95% CI 28-59), and yielded durable remissions. The most common unique toxicity with ENA was differentiation syndrome that occurred in 20% of patients. In pts who did not achieve CR/CRi with ENAm, a subset of patients achieved CR/CRi with addition of AZA. This combined approach of serial therapy with ENA monotherapy followed by AZA addition in pts with sub-optimal response resulted in a mOS exceeding 2 years for pts enrolled on study. Further focus on improving response among patients with IDH2 R172 mutations, identifying subsets of pts not responding to ENA monotherapy, and integrating new targeted agents into this treatment regimen are warranted.
Abhishek Maiti, Courtney D. DiNardo, Tapan M. Kadia, et al.
Authors Conclusion from the Abstract: DEC10-VEN represents an appropriate salvage therapy comparable to non-venetoclax based intensive chemotherapy regimens in younger pts with R/R AML and can serve as a bridge to SCT. This regimen provides an appropriate backbone for adding novel therapies in the R/R setting.